Overview of D3-Vicotrat

What is D3-Vicotrat? Overview and Quick Facts

D3-Vicotrat is a pharmaceutical preparation and brand name containing the essential compound Colecalciferol. The preparation is monocomponent, meaning it provides only this single active ingredient. This substance is chemically defined as a secosteroid and biologically as a prohormone, functioning fundamentally to support the body’s mineral balance.

Quick Facts
Active ingredient	Colecalciferol (Vitamin D3)
Form	Oral solution (liquid drops)
Pharmacological class	Fat-Soluble Vitamin, Secosteroid
Common use	Supports mineral balance and skeletal structure
Origin	Naturally occurring compound, also commercially synthesized

What Class of Medicine is D3-Vicotrat?

D3-Vicotrat belongs to the pharmacological class of Fat-Soluble Vitamins, specifically providing Colecalciferol (Vitamin D3). This substance is identical to the Vitamin D3 naturally synthesized in the human skin upon UVB light exposure, classifying it as a naturally occurring compound that is also synthesized commercially. As a nutrient necessary for health, Colecalciferol is widely utilized in clinical practice and is recognized for its role in supporting numerous bodily functions.

Composition and Form: The Oil-Based Solution

D3-Vicotrat is commonly supplied as an oral solution in liquid drops intended for oral administration. The composition features the active ingredient, Colecalciferol, dissolved in an oil-based vehicle, such as neutral oils or medium-chain triglycerides. This specific oil-based format is a distinctive feature of D3-Vicotrat preparations, chosen because Colecalciferol is a fat-soluble vitamin; the lipid vehicle ensures optimal chemical stability and enhances the compound's absorption through the digestive tract. The liquid, drop format often positions D3-Vicotrat as a preferred choice for treating target patient groups, such as infants and children, who require easily administered doses.

Core Role of Colecalciferol: The General Purpose

The general therapeutic purpose of Colecalciferol is to support the body's processes involving calcium homeostasis and skeletal structural integrity. The compound's function is to significantly enhance the absorption of both calcium and phosphate from the diet within the intestine. This primary regulatory action ensures sufficient mineral availability for bone mineralization, while also providing support for normal muscle function and contributing to the modulation of the immune system.

Regulatory References

National Institutes of Health (NIH)

What side effects are possible with D3-Vicotrat?

Possible side effects and safety information

Official regulatory documents classify the primary safety concerns of Colecalciferol (Vitamin D3) as effects on mineral metabolism, consistent with its biological role. These effects, though generally uncommon, include Hypercalcemia (abnormally high blood calcium) and Hypercalciuria (excessive calcium in the urine). The appearance of these adverse reactions is typically associated with the prolonged administration of high doses (chronic overdosage), which defines the principal dose-related safety pattern.

Less frequently reported adverse reactions, classified as rare, involve Skin and Subcutaneous Tissue Disorders such as pruritus (itching), rash, and urticaria (hives). Additional Gastrointestinal Disorders like nausea, constipation, abdominal pain, and diarrhea have also been documented, though their specific frequency is often categorized as not known in official labeling.

Adverse Reaction Type	Frequency (Official Classification)	System-Organ Class
Hypercalcemia, Hypercalciuria	Uncommon	Metabolism and Nutrition Disorders
Pruritus, Rash, Urticaria	Rare	Skin and Subcutaneous Tissue Disorders

Serious adverse reactions documented in official sources are related to severe, uncontrolled hypercalcemia, which can lead to complications such as renal impairment (nephrocalcinosis) and effects on the central nervous system or heart. Safety restrictions mandate that this medicine is contraindicated for use in individuals with existing Hypervitaminosis D or pre-existing Hypercalcemia or Hypercalciuria. Caution is also specifically noted for patients with renal impairment due to increased risk of hypercalcemia.

Overdose and Emergency Response

The official regulatory profile for D3-Vicotrat overdose is classified as Hypervitaminosis D, stemming from chronic or acute exposure to excessive doses of Colecalciferol. The primary physiological finding is hypercalcemia (abnormally high blood calcium), which drives the documented multisystemic manifestations.

Documented Overdose Presentations

Overdose presentations involve symptoms affecting renal, gastrointestinal, and neuro-muscular systems. Documented clinical signs include fatigue, muscle weakness, confusion, anorexia, vomiting, polyuria (excessive urination), and excessive thirst.
Serious outcomes cited in official labeling include irreversible renal impairment, cardiac arrhythmias, and metastatic soft-tissue calcification. In extreme cases, the condition may progress to stupor or coma.
Population-specific warnings exist, noting the increased risk in immobilized patients and potential developmental harm if hypercalcemia occurs during pregnancy.

Immediate Actions and When to Seek Urgent Help

Regulatory instructions mandate that treatment must be discontinued immediately and patients must seek emergency medical attention or call a Poison Control Center if severe symptoms occur or overdose is suspected.
Immediate medical help is required if the victim has collapsed, had a seizure, has trouble breathing, or cannot be awakened.
Management is supportive, focusing on hydration and pharmacologic correction of hypercalcemia, as no specific antidote is known.

The official regulatory profile defines this toxicity by the progression from elevated calcium levels to life-threatening end-organ damage, explicitly establishing the conditions under which urgent professional help must be sought for supportive management and mandatory monitoring.

Therapeutic Uses of D3-Vicotrat

Main Uses of D3-Vicotrat

D3-Vicotrat is used primarily to address vitamin D deficiency and manage conditions related to calcium metabolism. Its applications focus on maintaining adequate levels of cholecalciferol (vitamin D3) in the body, which is essential for various physiological processes.

Prevention and Treatment of Vitamin D Deficiency

The medication is used to prevent and treat vitamin D deficiency in children and adults. This deficiency can occur due to inadequate sunlight exposure, malabsorption issues, or insufficient dietary intake. Ensuring adequate vitamin D levels is necessary for the proper functioning of the musculoskeletal system.

Support in Bone Health Management

D3-Vicotrat is often utilized as a supportive treatment for specific bone-related conditions:

Rickets: In children, it is used to treat rickets, a softening and weakening of bones caused by extreme and prolonged vitamin D deficiency.
Osteomalacia: In adults, it addresses osteomalacia, which involves the softening of the bones and can lead to bone pain and increased fragility.
Osteoporosis: It is used as an adjunct to specific osteoporosis treatments in patients who are at risk of vitamin D deficiency. In this context, it helps ensure the body can effectively utilize calcium to maintain bone density.

Hypoparathyroidism

The medication may be used in the management of chronic hypoparathyroidism, a condition where the parathyroid glands do not produce enough parathyroid hormone, leading to low calcium levels. Vitamin D3 helps regulate calcium and phosphate levels in these patients.

Benefits of D3-Vicotrat

Calcium and Phosphate Absorption

The primary benefit of D3-Vicotrat is its ability to facilitate the absorption of calcium and phosphate from the intestines into the bloodstream. These minerals are the building blocks of bone tissue and are vital for maintaining the structural integrity of the skeleton.

Bone Mineralization

By maintaining appropriate levels of calcium and phosphorus, D3-Vicotrat supports the mineralization of the bone matrix. This process is essential for developing strong bones in children and preserving bone strength in the elderly, thereby reducing the risk of fractures.

Neuromuscular Function

Adequate vitamin D levels contribute to normal muscle function. This is particularly beneficial for older adults, as improved muscle strength and coordination can help maintain stability and reduce the likelihood of falls.

Regulatory References

NIH MedlinePlus overview on Cholecalciferol

Eligibility and Restrictions for Use

D3-Vicotrat eligibility is determined by strict metabolic, renal, and physiological criteria established in official regulatory documents. Use is absolutely contraindicated in several groups.

Eligibility Scope	Status	Affected Population
Contraindications	Prohibited	Patients with Hypercalcaemia, Hypervitaminosis D, Hypercalciuria, or Nephrolithiasis (kidney stones).
Severe Impairment	Prohibited	Individuals with Severe Renal Impairment are not eligible.
Age Eligibility	Allowed / Restricted	Adults and Adolescents are generally eligible. Some high-dose formulations are not recommended for children under 12 years.
Conditional Use	Caution Required	Patients with Sarcoidosis or pre-existing (non-severe) Renal Impairment must use the medicine with caution and under strict monitoring.
Pregnancy/Lactation	Restricted	High-dose use is not recommended. Use is permitted at low, necessary doses to treat deficiency during pregnancy and breastfeeding, with mandatory monitoring.

Regulatory documents define eligibility severity classification as Contraindicated (absolute prohibition), Not Recommended (use restricted or generally avoided), or Permitted with Caution (mandatory monitoring required). This official structure ensures the drug is not administered when pre-existing metabolic conditions could lead to potentially harmful calcium overload.

What should I know about interactions with other medicines?

Interactions Affecting Absorption and Exposure

The fat-soluble nature of Colecalciferol means certain agents can reduce its systemic exposure. Ion-exchange resins (such as cholestyramine) and laxatives containing mineral oil reduce the gastrointestinal absorption of Colecalciferol; therefore, the administration of these substances requires separation in time as noted in regulatory documents.

Some medicines also alter the clearance of Colecalciferol. Anticonvulsants (e.g., phenytoin) and agents like rifampicin and glucocorticoids may reduce the therapeutic effect of Colecalciferol through hepatic enzyme induction, increasing its metabolic catabolism. Actinomycin and imidazole antifungals are documented to interfere with the final activation step of Colecalciferol.

Interactions Affecting Mineral Balance

Co-administration with other substances can lead to additive pharmacodynamic effects on the body’s mineral balance. Thiazide diuretics (such as hydrochlorothiazide) increase the risk of hypercalcaemia due to reduced urinary calcium elimination. If hypercalcaemia occurs, the effects of cardiac glycosides (e.g., digoxin) may be potentiated, increasing the risk of cardiac arrhythmias.

Interacting Substance	Officially Documented Interaction Outcome
Magnesium-containing products	Increased risk of hypermagnesemia, particularly in patients with impaired renal function.
Dietary Supplements	Additive effects on mineral levels when combined with a diet high in calcium, phosphorus, or Vitamin D supplements.

The condition Pseudohypoparathyroidism restricts the standard use of Colecalciferol due to an altered response documented in regulatory prescribing information.

Mechanism of Action

The mechanism of D3-Vicotrat begins with the prohormone Colecalciferol undergoing two mandatory hydroxylation steps in the liver and kidney to yield the active hormone, Calcitriol. This hormone functions as an agonist for the nuclear Vitamin D Receptor (VDR), found throughout the body. The VDR complex binds directly to DNA, initiating the gene transcription of key proteins. This genomic action modulates cell expression resulting in increased mineral retention and absorption.

This transcriptional regulation primarily targets epithelial cells in the intestine and kidney. By increasing the expression of specific transport proteins (e.g., Calbindin), the active hormone increases the intestinal absorption of calcium and phosphate from the diet while simultaneously promoting the reabsorption of these minerals in the renal tubules. This systemic increase in circulating minerals provides the substrates necessary for bone mineralization and influences calcium handling required for muscle cell activity. Beyond mineral transport, the VDR complex modulates signaling pathways (like RANKL) in bone and affects differentiation and cytokine expression in immune cells, representing a distinct non-skeletal pathway consequence.

Dosage and Administration Information

How to Use D3-Vicotrat

D3-Vicotrat is administered through the oral route as a liquid solution, consistent with its labeled dosage form. Since Colecalciferol is a fat-soluble compound, it is recommended that the medicine be taken with a meal or food containing fat to promote optimal absorption through the digestive tract. The usage follows distinct administrative patterns depending on the therapeutic phase.

For the correction of established deficiency, the regimen typically involves a short-term, high-dose course, often utilizing weekly or bi-weekly administrations of large doses (e.g., up to 50,000 International Units (IU)) over several weeks. This is followed by a transition to the maintenance phase, characterized by lower, ongoing administration, generally falling within the range of 800 IU to 2,000 IU taken once daily.

The liquid dose must be measured precisely using the calibrated dropper provided, as the strength is defined per unit volume, necessitating accurate measurement for safe administration. Specific usage rules are provided for different patient populations: Pediatric patients, particularly infants, follow tailored dosing schedules (e.g., 400 IU daily for prophylaxis) that are distinct from adult regimens. If a dose is missed, guidance advises taking it as soon as it is remembered, but if it is nearly time for the next scheduled dose, the missed dose should be skipped to prevent a double dose. This two-phase, measured-intake structure defines the standardized protocol for the medication’s use.

Recent Clinical Evidence

Evidence for Deficiency Correction and Bone Health Support

Research has examined the physiological effects of Colecalciferol (D3-Vicotrat) in addressing states of Vitamin D deficiency. Randomized Controlled Trials (RCTs) consistently documented that the intervention was followed by an increase in serum 25(OH)D concentrations, demonstrating a change in the circulating biomarker status. This research base is extensive for the correction of low Vitamin D levels across diverse populations. The scientific community is still working to define the specific populations that may experience a difference in clinical outcomes.

Studies were also conducted for bone health conditions like rickets in children and osteomalacia in adults. Research examined outcomes related to skeletal structural integrity and patterns of change in symptoms like bone pain and muscle weakness. The strongest evidence was observed in individuals presenting with severe, overt nutritional deficiencies.

Osteoporosis, Fracture Risk, and Research Gaps

The research base for the supportive management of osteoporosis and fracture risk in older adults involves diverse findings. Large-scale RCTs and meta-analyses were evaluated in populations at risk of falls. Findings regarding the primary endpoints were mixed across various studies. While some meta-analyses reported an association with a pattern of lower fracture incidence when Colecalciferol was used, often combined with calcium, reports from many individual RCTs exploring Colecalciferol used alone are often described as inconsistent or inconclusive regarding fracture incidence.

This evidence contains several research limitation frames. Long-term follow-up duration is often required (three to seven years) to capture fracture endpoints, and limited information is available for the durability of the response over these extended periods. Data for individuals with milder deficiency or multiple co-occurring medical conditions remain limited, and research exploring non-skeletal outcomes is ongoing, but certainty remains low for many of these findings.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about D3-Vicotrat (FAQ)

Q: Does D3-Vicotrat require a medical prescription?

D3-Vicotrat contains the compound Colecalciferol, which is widely recognized by global health agencies. This ingredient is available both as an over-the-counter (OTC) supplement and as a higher-strength, prescription-only medicine. Whether a prescription is defined as necessary depends on the specific dosage strength and the condition being treated.

Q: How does D3-Vicotrat's use differ from standard vitamin D supplements?

Official product information states that D3-Vicotrat is used for both long-term, lower-dose prevention (similar to OTC supplements) and for short-term, high-dose prescription 'loading' regimens. These high-dose regimens are strictly controlled and used to rapidly correct severe deficiency, which distinguishes its use from standard over-the-counter products.

Q: Are there any common over-the-counter medications that interact with D3-Vicotrat?

Regulatory documents state that certain non-prescription drugs may affect D3-Vicotrat. For instance, some weight loss drugs like orlistat may decrease how much Colecalciferol is absorbed. Additionally, certain diuretics used for fluid control, such as thiazides, are described as potentially raising blood calcium levels when combined with this medicine.

Q: Is there a known interaction between D3-Vicotrat and blood thinners?

The active ingredient in D3-Vicotrat does not directly interfere with the way blood thinners (anticoagulants) like warfarin work. However, high levels of Vitamin D may require closer monitoring, as they have been associated with changes in the action of blood thinners as defined in official documents.

Q: Can D3-Vicotrat be associated with changes in sleep patterns?

Changes in sleep patterns are not listed as common side effects of D3-Vicotrat at therapeutic doses. However, in cases of severe overdose, the resulting condition, called hypercalcemia, may be associated with neurological symptoms. These may include confusion, drowsiness, and mental disturbance.

Q: Are headaches listed among the possible side effects of D3-Vicotrat?

Headache is noted in official regulatory documents as a possible symptom associated with Vitamin D intoxication or hypercalcemia (abnormally high blood calcium). It is not listed as a common side effect at standard therapeutic doses.

Q: Is D3-Vicotrat suitable for individuals with pre-existing liver conditions?

Regulatory information indicates that D3-Vicotrat is generally suitable for use in individuals with liver conditions (hepatic impairment). Official documents note that no dosage adjustment is typically defined as necessary for these patients.

Q: Is the medication usually continued long-term, or is it for short-term use?

The medicine is used for both short-term correction and long-term maintenance. Treatment usually begins with a short, high-dose course to rapidly correct an established deficiency. This phase is then followed by a lower, ongoing maintenance dose to prevent the deficiency from returning.

Q: Is it true that D3-Vicotrat is only for cases of severe medical deficiency?

No, the medicine is not limited to only severe deficiency. Official product documents indicate its use for the correction of severe deficiency, treatment of moderate insufficiency, and long-term maintenance therapy to prevent deficiency.

Q: How long does it typically take for D3-Vicotrat to show its intended effect?

The intended effect of D3-Vicotrat is to raise the circulating levels of 25-hydroxyvitamin D, which is the main transported metabolite. Due to this metabolite's half-life, significant changes in serum levels are gradual and may take several weeks to occur.

Q: How quickly is D3-Vicotrat generally cleared from the body's system?

Colecalciferol and its metabolites are primarily eliminated from the body via the bile and faeces. According to pharmacokinetic studies, the active compound has a relatively long half-life, meaning it remains in the body's system for approximately two months.

Q: How is D3-Vicotrat described as different from other similar prescription products?

Differences among similar prescription products often relate to the specific dosage form (e.g., liquid drops vs. capsules/tablets), strength (IU), or the excipients and vehicle used in the formulation. D3-Vicotrat is often noted for its oil-based liquid format.

Q: Does D3-Vicotrat need to be taken at a specific time of day?

Official guidance describes taking the medication at around the same time every day to support consistent levels of the active ingredient in the body. Furthermore, the instructions note taking it with a meal or fatty food to optimize absorption.

Q: Is D3-Vicotrat known to cause any changes in weight?

Official documents list weight loss as one of the possible non-specific symptoms that may be associated with Vitamin D intoxication (overdose) or hypercalcemia. These effects are typically non-specific and are a sign that the patient may be experiencing symptoms of hypercalcemia.

Q: Are there any specific lifestyle factors mentioned that could impact D3-Vicotrat's effectiveness?

Official warnings note that both alcohol and tobacco use may cause interactions or affect the drug's stability. Official documents mention the importance of maintaining consistent dietary habits, especially regarding calcium intake, while using this medicine.

Q: What is the current regulatory status of D3-Vicotrat in major global health agencies?

Colecalciferol is a substance widely recognized by major global health agencies, including the FDA and EMA. It is officially approved for various uses as a nutritional element and a prescription medicine to treat or prevent Vitamin D deficiency.

Q: Can D3-Vicotrat cause dry mouth or changes in taste?

Changes in taste and sensation are uncommon but have been noted in regulatory documentation. Dry mouth, increased thirst, and a metallic taste are listed as uncharacteristic symptoms that may appear in cases of severe overdose or intoxication.

Q: Is it necessary to have certain levels checked by a healthcare provider while taking D3-Vicotrat?

Official documents state that monitoring is necessary. During long-term treatment or high-dose courses, official regulatory documents define specific parameters that should be monitored, including blood calcium levels, urinary calcium excretion, and kidney function (via serum creatinine).

Q: What are the symptoms of an allergic reaction to D3-Vicotrat that are mentioned in official warnings?

Regulatory documents note that hypersensitivity reactions may occur. Possible symptoms include pruritus (itching), skin rash, and urticaria (hives). In rare cases, more severe swelling of the face or throat has also been noted.

How should D3-Vicotrat be stored and disposed of?

How to Store and Dispose of D3-Vicotrat

The storage and disposal of D3-Vicotrat (Cholecalciferol) must follow the conditions specified in the official regulatory labeling.

Official Storage Conditions

Mandatory Storage: The medicine must be kept out of the sight and reach of children at all times. D3-Vicotrat should be stored in its original container and protected from light.

Temperature Control: Storage temperature must not exceed 25 C. The product must not be used after the expiry date printed on the packaging. For the ampoule form, any content remaining after opening must be immediately discarded.

Disposal Instructions

Unused or expired D3-Vicotrat must not be thrown away via household waste or poured into wastewater. Disposal must be completed according to local regulatory requirements, typically by returning the medicine to a pharmacy or a designated pharmaceutical waste collection point.

D3-Vicotrat